ClinicalTrials.gg
RecruitingNCT05022524Updated Oct 5, 2023

Exploring Novel Uses of Microbiota Therapy for Managing the Side Effects of Psychiatric Pharmaceutical Interventions

A Phase 1 interventional study of Acetate (Apple Cider Vinegar) in Depression, Anxiety, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Recruiting at 1 site in Canada. Open to participants aged 16 Years to 25 Years. Per ClinicalTrials.gov, last updated 2023-10-05.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
16 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Depression by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's — 7 open to participants now, 7 under way, none of them phase 3. Depression · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.

Planned enrollment
13th of 14
10 · median 38
Started
2022
with 2 others
Phase 1
2 of 16
1 open now
Registered
10th of 16
by date

Among the 16 studies in Depression by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, this one is the 13th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is one of 2 in phase 1, and was the 10th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

7 of the 16 studies in Depression by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 16 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Depression by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, or all of them as a file.
02

Study summary

To determine the feasibility of whether the addition of key prebiotics administered orally can mitigate some of the most problematic side-effects of the most common psychiatric medications - weight gain and metabolic abnormalities caused by some antidepressants, mood stabilizers and antipsychotics. In the initial part of the study, we aim to determine feasibility of the study and evaluate participant compliance.

Our clinical trial will encourage the growth of Akkermansia muciniphila (AM) through enteric-coated orally-administered acetate (apple cider vinegar powder in capsules) in 16-to-28 year-old patients who have already experienced weight gain while on stable doses of psychiatric medication, with the hypothesis that the addition of this prebiotic will result in alterations in gut microbiota and measurable weight loss, as well as improvement in metabolic measurements.

Primary Objective:

  • To evaluate feasibility of using acetate in a large-scale clinical trial, including considerations for protocol, study agent, recruitment, retention, adverse events, budget, staff, facility, and patient experience
  • To estimate effect size of change in AM relative abundance by measuring pre- and post-intervention levels for use in designing future large-scale clinical trials

Secondary Objectives:

  • To determine whether acetate administered orally shows an observable effect on weight gain as a side effect from antidepressants, mood stabilizers, and/or antipsychotics in a sample of participants already on stable doses of at least one of these medications
  • To determine changes in metabolic syndrome profile, as indicated by blood pressure and high-density lipoprotein.
  • To conduct preliminary analyses on any possible changes in mood/anxiety symptoms pre- versus post-intervention
  • To identify and define other potential confounders or effect modifiers of our primary and secondary objectives that should be considered in future study designs
03

Conditions studied

  • Depression, Anxiety

Keywords

  • Probiotics
  • Psychiatry
  • Weight
04

Who can participate

Ages eligible
16 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For an eligible patient, all inclusion criteria must be answered "yes"

  1. Signed obtained prior to any study-related activities
  2. Patients of FEMAP who are between the ages of 16 and 28
  3. Currently on a stable dose of an antidepressant, mood stabilizer, and/or antipsychotic drug AND have experienced what they deem to be problematic weight gain (approximately greater than 5% of initial body weight) that was temporally linked with initiating the drug, as confirmed by a psychiatrist
  4. Have a of ≥ 21.7 kg/m2 (midpoint of normal BMI (18.5-24.9).

Exclusion criteria

Exclusion Criteria:

  1. Participants who are unable to follow multi-step instructions independently, as determined by the treating psychiatrist.
  2. Participants who are pregnant or planning to get pregnant
  3. Patients on medications that have weight loss as a potential side effect i.e. topiramate, metformin, psychostimulants.
  4. Current active eating disorder i.e. bulimia nervosa, binge eating disorder, anorexia nervosa
  5. Currently on a weight-loss diet plan i.e. ketogenic diet, detox diet
  6. Currently using a medication for weight loss i.e. Contrave (bupropion / naltrexone), Saxenda (liraglutide)
  7. Current use of dietary supplements for weight loss i.e. garcinia cambogia; or use within 4 weeks prior to study initiation
  8. Bowel surgery
  9. Crohn's disease or other bowel conditions
  10. Blood/bleeding/liver/kidney disorders
  11. Currently enrolled in other clinical trial which may affect their study outcome
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Transition-Age Adults

    16-25 year old patients on stable dose of antipsychotic medication for treatment of depression or anxiety.

    Dietary Supplement: Acetate (Apple Cider Vinegar)

Interventions

  • Dietary supplementAcetate (Apple Cider Vinegar)

    Consumer-grade apple cider vinegar (ACV) capsules will have extra enteric coating applied for delivery further into the GI tract.

06

What researchers measure

Primary outcomes

  1. Feasibility: Recruitment success

    Number of potential participants approached to number expressing interest, and number invited to number recruited (recruitment success)

    Time frame: 5 months

  2. Feasibility: Retention

    Number recruited to number retained (attrition)

    Time frame: 5 months

  3. Feasibility: Adherence

    Number adhering to intervention protocol quantified through number of capsules returned at end of trial

    Time frame: 5 months

  4. Feasibility: Adverse Events

    A study-specific data form for collecting adverse events

    Time frame: 5 months

  5. Akkermansia Muciniphila abundance

    Relative abundance (proportion) of AM in stool at inception compared to all other species identified, and change in relative abundance from pre- to post-intervention

    Time frame: 5 months

Secondary outcomes

  1. Body Weight

    Standard Medical-grade floor scale

    Time frame: 5 months, recorded monthly

  2. Metabolic Indicator: Blood pressure

    Blood pressure using medical-grade arm cuff (mm/Hg, Systolic and Diastolic)

    Time frame: 5 months

  3. Metabolic Indicator: High-Density Lipoproteins

    HDL cholesterol assayed from antecubital blood draw, expressed in mg/dL

    Time frame: 5 months

  4. Mood: Depression

    Quick Inventory of Depressive Symptomatology (QIDS-SR, Rush et al. 2003) - baseline scores to describe the sample, change from pre-post intervention to explore potential treatment effect

    Time frame: 5 months, captured monthly

  5. Mood: Anxiety

    Overall Anxiety Severity and Impairment Scale (OASIS, Barlow et al. 2010) - baseline scores to describe the sample, change from pre-post intervention to explore potential treatment effect

    Time frame: 5 months, captured monthly

07

Study locations

1 of 1 sites recruiting
  • First Episode Mood and Anxiety Disorders Program (FEMAP)
    London, Ontario N6A 3H8, Canada
    Recruiting
    • Elizabeth A Osuch, MD · ContactFEMAP@lhsc.on.ca · +1-519-646-6000
    • David M Walton, PhD · Sub investigator
    • Jeremy P Burton, PhD · Sub investigator
    • Colleen O'Connor, PhD · Sub investigator
    • Ju Eun Lee, MB, MSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — We do not plan to share IPD with other researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Jun 2024, 24 months after the start.

Of 82 non-industry phase 1 interventional studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 61. This study's planned 24 months is below that.

Counting every sponsor, half of 102 studies reached it within 27 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2021
First posted
Aug 26, 2021
StartActual
Jun 1, 2022
Primary completionEst.
Jun 30, 2024
CompletionEst.
Aug 31, 2024
Last update
Oct 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05022524
Responsible party
Sponsor
First posted
Aug 26, 2021
Start date
Jun 1, 2022
Primary completion
Jun 30, 2024 (estimated)
Completion
Aug 31, 2024 (estimated)
Last update
Oct 5, 2023

Study contacts

Elizabeth Osuch, MD
Contact
elizabeth.osuch@lhsc.on.ca
519-646-6000 ext. 65188

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion